title: Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes.
abstract: BACKGROUND
  Patients with rectal cancer exhibit a wide spectrum of responses to chemoradiotherapy. Several gene expression signatures have been reported to predict the response to chemoradiotherapy in rectal cancer, but the lack of practical assays has restricted the clinical use of this technique.
  
  
  OBJECTIVE
  We aimed to identify a set of discriminating genes that can be used for the clinical prediction of response to chemoradiotherapy in rectal cancer.
  
  
  METHODS
  This study is a retrospective analysis of tumor samples in a single institute.
  
  
  METHODS
  Sixty-two patients who underwent preoperative chemoradiotherapy were studied.
  
  
  METHODS
  Gene expression was initially studied in 46 training samples by microarray analysis, and the association between gene expression and response to chemoradiotherapy was evaluated. Quantitative reverse transcriptase polymerase chain reaction was performed to validate the microarray expression levels of the discriminating genes. We developed a gene expression model for the prediction of response to chemoradiotherapy based on the reverse transcriptase polymerase chain reaction findings and validated it by using 16 independent test samples.
  
  
  RESULTS
  We identified 24 discriminating probes with expression levels that differed significantly between responders and nonresponders. Among 18 genes identified by Gene Symbol, real-time reverse transcriptase polymerase chain reaction showed significant differences in the expression of 16 genes between responders and nonresponders. We constructed a predictive model by using different sets of these 16 genes, and the highest accuracy rate (89.1%) was obtained by using LRRIQ3, FRMD3, SAMD5, and TMC7. The predictive accuracy rate of this 4-gene signature in the independent set of 16 patients was 81.3%.
  
  
  CONCLUSIONS
  Validation in a different and large cohort of patients is necessary.
  
  
  CONCLUSIONS
  The 4-gene signature identified in this study is closely associated with response to chemoradiotherapy in rectal cancer.
authors: 1Department of Surgical Oncology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan 2Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Harish, Kawauchi-cho, Tokushima, Japan 3Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan 4Department of Surgery, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
authors: Toshiaki
authors: T
authors: Watanabe
authors: Takashi
authors: T
authors: Kobunai
authors: Takashi
authors: T
authors: Akiyoshi
authors: Keiji
authors: K
authors: Matsuda
authors: Soichiro
authors: S
authors: Ishihara
authors: Keijiro
authors: K
authors: Nozawa
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D059186:Chemoradiotherapy, Adjuvant; D003661:Decision Support Techniques; D005260:Female; D020869:Gene Expression Profiling; D005819:Genetic Markers; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D020411:Oligonucleotide Array Sequence Analysis; D025341:Principal Component Analysis; D060888:Real-Time Polymerase Chain Reaction; D012004:Rectal Neoplasms / Q000235:genetics / Q000628:therapy*; D012007:Rectum / Q000601:surgery*; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C562024:FRMD3 protein, human; D005819:Genetic Markers; D025521:Tumor Suppressor Proteins